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Identity 
Other names: BCL5, LAZ3, ZBTB27, ZNF51, 
BCL6A 
HGNC (Hugo): BCL6 
Location: 3q27.3 
Local order: Gene orientation: telomere - 5' BCL6 3' - 
centromere. 
 




The gene is encoded by 11 exons that are located on 
chromosome 3q27 and is 24,3 kb. The 5' portion 
encodes for the BTB/POZ domain (broad-
complex/tramtrack/bric-a-brac/pox virus/zinc finger), 
while the 3' end encodes for 6 DNA binding zinc 
fingers. The first ATG occurs in exon 3. 
Transcription 
3,8 kb mRNA. 
Protein 
Description 
The protein product is 706 amino acids with an 
estimated molecular weight of 78,8 kDa. 
Expression 
Normally expressed in germinal center B and T cells, 





Protein domains and functions 
The protein can bind to sequence specific DNA and 
repress its transcription in addition to recruiting other 
protein repressors. The DNA binding is mediated 
through the consensus sequence TTCCT(A/C)GAA 
(see below), while the protein-protein interactions are 
mediated through the BTB/POZ domain and it has been 
shown to interact with other zinc finger proteins and 
corepressors (including Histone Deacetylase 1 
(HDAC1) and NCOR2 (Silencing Mediator of Retinoid 
and Thryoid Receptor 1 (SMRT1))). The carboxy 
terminus, on the other hand, is responsible for sequence 
specific DNA binding through its 6 zinc fingers. 
 










Consensus DNA motifs recognized by BCL6 
The Zn fingers of BCL6 binds to DNA and recognizes 
specific DNA motifs: the M00424 motif, a consensus 
sequence for the NKX-homeobox family of 
transcription factors, the M2 motif, which mimics an 
M00424 half site; and the M0 motif (see details in 
Basso et al., 2010). 
BCL6 cellular function 
- BCL6 cellular function in germinal centers of 
lymph nodes follicles 
Mature naïve B cells migrate from the bone marrow t 
lymphoid nodes, meet the antigen, they are stimulated 
to proliferate and further differentiate into centroblasts 
in germinal centers (GC) of lymphoid follicles.  
There, cells are subjects to somatic hypermutation and 
class switch recombination, to further differenciate into 
memory B cells or plasma cells. This process also 
requires the presence of follicular helper T cells.  
BCL6 has a major role in this process. In particular, 
BCL6 prevents ATM and TP53 (Phan et al., 2004) to 
induce apoptosis in response to DNA rearrangements 
such as those necessary for somatic hypermutation and 
class switch recombination processes.  
BCL6 is therefore essential for normal B cell 
development (reviews in Albagli-Curiel, 2003; Jardin 
et al., 2007; Parekh et al., 2008; Basso and Dalla-
Favera, 2010; Pellicano and Holyoake, 2011; Wagner 
et al., 2011; Basso and Dalla-Favera, 2012; Okada et 
al., 2012). 
- T follicular helper cells 
BCL6 is essential for the development of follicular 
helper T (Tfh) cells. Tfh cells are defined by the 
expression of the surface markers CXCR5 and PD-1 
and synthesis of IL4 and IL21. BCL6 upregulation of B 
cells in the outer follicle sustains their interactions with 
helper T cells and allows them to enter the germinal 
centers (GC) region (Poholek et al., 2010; Kitano et al., 
2011; Baumjohann et al., 2011). ICOS induces BCL6, 
and BCL6 then induces CXCR5.  
Tfh cells were lost in the absence of B cells, 
demonstrating a B cell requirement for maintenance of 
BCL6 and Tfh cell commitment (Choi et al., 2011). 
BCL6 and MAF cooperate to induce Tfh cell 
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- Other tissues 
BCL6 promotes survival of olfactory sensory neurons 
(Otaki etal., 2010). 
BCL6 associate to NACC1 in brain regions (Korutla et 
al., 2009). 
BCL6 forms a complex with BCOR on the promoters 
of Notch target genes in Xenopus embryos (Sakano et 
al., 2010). 
BCL6-overexpression inhibits osteoclastogenesis, and
the PRDM1 (Blimp-1)/BCL6 balance is essential in 
regulating the bone homeostasis by controlling 
osteoclastogenesis (Miyauchi et al., 2010). BCL6 
controls the expression of the CC-type chemokine 
genes and attenuates allergic airway inflammation in 
pulmonary epithelium (Seto et al. 2011). 
BCL6 repression activity 
BCL6 binds to DNA as a homodimer and recruits co-
repressor molecules, which, in turn, recruit class I and 
II histone deacetylases. BCL6 and histone deacetylases 
(HDACs) form stable complexes. BCL6 binds HDACs 
both directly through its C-terminal Zn fingers and 
through its N-terminal BTB/POZ domain and indirectly 
by recruiting several co-repressors such as BCOR, 
NCOR1, NCOR2 (which bind in a mutually exclusive 
way to the BTB/POZ domain), CTBP1 (which binds 
the BTB/POZ and the PEST domains), and MTA3  
(which binds the PEST domain). Deacetylation of 
histones leads to transcriptional repression of BCL6 
targets. 
BCL6 interacts with ZBTB17 to repress CDKN1A and 
BCL2 (Phan et al., 2005). BCL6 has also been found to 
interact with other POK family members ((POZ and 
Krüppel)/ZBTB (zing finger and BTB) protein family) 
such as ZBTB7A (LRF) and ZBTB16 (PLZF). 
BCL6 targets 
An integrated biochemical and computational approach 
has recently identified thousands of BCL6 direct target 
genes, including B cell receptor (BCR; note: nothing to 
do with BCR, the partner of ABL1) and CD40 
signaling genes (involved in signal transduction, 
MAPK activation, NF-AT activation, and NF-kB 
activation); T cell-mediated B-cell activation; apopt sis 
(BCL2, proteins involved in positive and negative 
regulation of the DISC complex and caspase activation, 
suggesting a role for BCL6 in balancing pro- and 
antiapoptotic programs in GC B cells); response to 
DNA damage (ATM, TP53, CDKN1A, ATR, CHEK1, 
TP53BP1...); interferon and cytokine signaling 
(interferon-type and interleukin receptors that lead to 
activation of JAK/STAT. STAT1, STAT3, and 
STAT5A were also found to be directly repressed by 
BCL6); Toll-like receptor signaling; TGFb receptor 
signaling; and WNT signaling (Basso et al., 2010). 
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BCL6 regulation  
- B cell receptor 
B cell receptor (BCR) induces BCL6 phosphorylation 
by MAPK1 on Ser333 and Ser343, which targets BCL-
6 for rapid degradation by the ubiquitin/proteasome 
pathway (Niu et al., 1998). FBXO11 promotes BCL6 
ubiquitylation and degradation (Duan et al., 2012). 
- DNA damage 
After DNA damage, the kinase ATM promotes BCL6 
phosphorylation; follows an interaction with PIN1 
required for BCL6 degradation (Phan et al., 2007). 
- EP300 
EP300 binds and acetylates BCL6, which inactivates 
BCL6 (acetylation disrupts the ability of BCL6 to 
recruit histone deacetylases). The same two pathways 
(HDAC pathway and SIRT2 pathway) that regulate 
acetylation-mediated activation of TP53 also control 
acetylation-mediated inactivation of BCL6 
(Bereshchenko et al., 2002). BCL6 represses the 
expression of EP300 and its cofactor BAT3 (Cerchietti 
et al., 2010). EP300 acetylates and activates PAX5 (He 
et al., 2011), which enhances BCL6. 
- Autoregulation 
BCL6 protein binds BCL6 gene promoter, and repress 
BCL6, mechanism of negative autoregulation 
(Pasqualucci et al., 2003). PATZ1 interacts with BCL6 
and is required for its negative autoregulation (Pero et 
al., 2012). 
- CD40 signaling 
CD40 signaling activates various pathways, including 
NF-kB, NF-AT, and AP-1 (Francis et al., 1995). ILF2 
(NF45) and ILF3 (NF90) form the nuclear factor of 
activated T-cells (NF-AT), a crucial transcription factor 
essential for productive T cell activation (Kao et al., 
1994). CD40 signalling reduces BCL6 expression, 
through induction of IRF4 by the NF-kB pathway 
(Saito et al., 2007). 
- PRDM1 (review in Crotty et al., 2010) 
JUND/AP-1 and activated STATs drive high BCL6 
expression in GC B cells (Arguni et al., 2006). STAT5 
up-regulates BCL6 expression (Scheeren et al., 2005); 
in contrast, STAT3 up-regulates PRDM1 (Diehl et al.,
2008) (the protein coded from PRDM1 is named 
Blimp-1). BCL6 directly promotes the expression of 
BACH2, which repress PRDM1 (Blimp-1). BCL6 also 
suppresses PRDM1 (Blimp-1) through repression of 
IRF4. IRF4 binds to and induces PRDM1. PRDM1 
(Blimp-1) abrogates BCL6. PAX5 (protein name: 
BSAP) contributes to BCL6 expression (Nera et al., 
2006; Tarlinton, 2011). PAX5 abrogates PRDM1 
(Blimp-1), which abrogates PAX5. BCL6 and PAX5 
promote the expression of AICDA and UNG (which 
have a major role in somatic hypermutation and class-
switch recombination) (Alinikula et al., 2011). BCL6 
positively regulates AICDA, IRF8, and MYB via 
repression of MIR155 (Basso et al., 2012). BCL6 
mediates transcriptional repression by recruiting 
HDACs.  
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MIR155 directly targets HDAC4 and indirectly 
attenuates BCL6 expression (Sandhu et al., 2012). 
PRDM1 (Blimp-1) represses BCL6, and also PAX5, 
MYC, and AICDA (review in Martins and Calame, 
2008).  
IRF8 is expressed at the high levels in germinal center 
(GC) B cells. IRF8 binds BCL6 promoter and activates 
BCL6 (Lee et al., 2006). 
It is also to be noted that IRF4 is involved in the 
t(6;14)(p25;q32) IRF4/IGH. PRDM1 (Blimp-1) is 
inactivated in about 50% of the activated B cell-like 
(ABC) subtype of diffuse large B cell lymphoma 
(ABC- DLBCL) (Mandelbaum et al., 2010). 
Homology 
BTB/POZ - Zinc Finger proteins (PLZF, HIC1, KUP, 
BAZF, ttk (drosophila), BrC (drosophila)...). 
Mutations 
Note 
Chromosomal translocations involving BCL6 are found 
in 40% of diffuse large B-cell lymphomas (DLBCL), 5-
10% of follicular lymphomas (FL), and 50% of nodular 
lymphocyte predominant Hodgkin lymphomas. 
Mutations in the autoregulatory region of BCL6 leads 
to a constitutive BCL6 expression (Pasqualucci et al., 
2003). 
IRF4 response elements in the BCL6 gene mediate 
repression of BCL6.  
Mutations in the IRF4 repression region of BCL6 gene 
also leads to constitutive expression of BCL6 (Saito et 
al., 2007). 
MYC, BCL2, and BCL6 rearrangements were detected 
in 6%, 15%, and 29% respectively of diffuse large B-
cell lymphoma (DLBCL) patients. Double or triple 
rearrangements were detected in 3% of these patients.  
MYC rearrangement was associated with a 
significantly worse overall survival. BCL6 
rearrangement also predicted a significantly shorter 
overall survival, especially for the non-GC phenotype 
(Akyurek et al., 2012). 
Implicated in 
3q27 rearrangements /NHL (non 
Hodgkin lymphomas) 
Disease 
B cell non-Hodgkin Lymphoma (B-NHL) 
Prognosis 
Generally considered to be a better prognosis if there is 
increased expression of BCL6. The mechanism by 
which its expression is increased does not seem to 
matter (ie different translocation partners increasing its 
expression results in the same prognosis). 
Cytogenetics 
3q27 rearrangements/aberrations are diverse and 
include: translocations, micro-deletions, point 
mutations and hypermutation.  
Approximately 50% of 3q27 translocations involves Ig 
genes at 14q32 (IgH), 2p12 (IgK) and 22q12 (IgL) (e.g. 
t(3;14)(q27;q32)). Less than half (~40%) include a 
variety of other chromosomal regions (1q21, 2q21, 
4p11, 5q31, 6p21, 7p12, 8q24, 9p13, 11q13, 11q23, 
12q11, 13q14-21, 14q11, 15q21; 16p11...).  
In addition, there are frequent bi-allelic alterations 
(translocation and deletion or mutation on the non-
translocated allele). 
Hybrid/Mutated gene 
hybrid gene and transcripts are formed following 
promoter substitution between BCL6 and its different 
partners.  
Chimeric transcripts are generally detected containing 
the 5' part of the gene partner fused to the normal 
BCL6 exon 2 splice acceptor site.  
In some cases reciprocal chimeric transcripts driven by 
the 5' regulatory region of BCL6 fused to the partne  
gene coding region, have been characterised. 
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- t(1;3)(q25;q27) the gene in 1q25 is GAS5 
- t(2;3)(p12;q27) the gene in 2p12 is IGK 
- t(3;3)(q25;q27) the gene in 3q25 is MBNL1 
- t(3;3)(q27;q27) the gene in 3q27 is ST6GAL1 
- t(3;3)(q27;q27) the gene in 3q27 is EIF4A2 
- t(3;3)(q27;q29) the gene in 3q29 is TFRC 
- t(3;4)(q27;p13) the gene in 4p13 is RHOH 
- t(3;6)(q27;p22) the gene in 6p22 is HIST1H4I 
- t(3;6)(q27;p21) the gene in 6p21 is PIM1 
- t(3;6)(q27;p21) the gene in 6p21 is SFRS3 
- t(3;6)(q27;q15) the gene in 6q15 is SNHG5 
- t(3;7)(q27;p12) the gene in 7p12 is IKZF1 
- t(3;7)(q27;q32) the gene in 7q32 is FRA7H 
- t(3;8)(q27;q24.1) the gene in 8q24.1 is MYC 
- t(3;9)(q27;p24) the gene in 9p24 is DMRT1 
- t(3;9)(q27;p11) the gene in 9p11 is GRHPR 
- t(3;11)(q27;q23) the gene in 11q23 is POU2AF1 
- t(3;12)(q27;p13) the gene in 12p13 is GAPDH 
- t(3;12)(q27;q12) the gene in 12q12 is LRMP 
- t(3;13)(q27;q14) the gene in 13q14 is LCP1 
- t(3;14)(q27;q32) the gene in 14q32 is IGH 
- t(3;14)(q27;q32) the gene in 14q32 is HSP90AA1 
- t(3;16)(q27;p13) the gene in 16p13 is CIITA 
- t(3;16)(q27;p11) the gene in 16p11 is IL21R 
- t(3;19)(q27;q13) the gene in 19q13 is NAPA 
- t(3;22)(q27;q11) the gene in 22q11 is IGL 
Abnormal protein 
No fusion protein. 
t(9;22)(q34;q11) leukemias 
Disease 
BCL6 enables Ph+ acute lymphoblastic leukaemia cells 
to survive BCR-ABL1 kinase inhibition (Duy et al. 
2011). 
In chronic myelogenous leukemia (CML), BCL6 acts 
as a critical effector downstream of FoxO in self-
renewal signaling of CML-initiating cells. Therefore, 
pharmacological inhibition of BCL6 may represent a 
novel strategy to eradicate leukemia-initiating cells in 
CML (Hurtz et al., 2011). 
Breast cancer 
Disease 
BCL6 protein is elevated in human breast cancers, 
especially in high-grade, poorly differentiated and 
metastatic breast cancer cases (Bos et al., 2003; 
Logarajah et al., 2003; Brill et al., 2010). PRL 
(prolactin) rapidly suppressed BCL6. Loss of PRL-
STAT5a signaling and concomitant upregulation of 
BCL6 may represent a regulatory switch facilitating 
undifferentiated histology and poor prognosis (Brill et 
al., 2010). 
Bladder transitional cell carcinoma 
Disease 
BCL6 protein overexpression is observed in half of the 
cases of transitional cell carcinoma.  
However, BCL6 over-expression has a negative 
correlation with the histological grade (Cho et al., 
2007). 
Soft tissue tumors 
Disease 
BCL6 expression is more frequent in malignant 
compared with benign/uncertain solitary fibrous 
tumors, as well as in leiomyosarcomas compared with
leiomyomas (Walters et al., 2011). 
Neuroblastoma 
Disease 
In the neuroblastic phenotype of neuroblastoma, BCL6 
expression is associated with increased time to relaps  
and increased overall survival (Chamdin et al., 2009). 
Gastric cancer 
Disease 
In a study of 100 gastric cancer cases, BCL6 was 
highly expressed in differentiated cancers and reduc  
or absent in undifferentiated cancers. However, 
survival was identical in BCL6-positive and BCL6-
negative cases (Hirata et al., 2009). 
Multiple myeloma 
Disease 
IL6 induces transcriptional up-regulation of BCL6 via 
JAK/STAT3 pathway. TNF (TNF alpha) up-regulates 
BCL6. BCL6 expression is mediated independantly via 
both JAK/STAT3 and NF-KB pathways in multiple 
myeloma cells (Hideshima et al., 2010). 
Breakpoints 
Note 
Clustered in a 3,3 kb EcoRI fragment (MTC) includind 
exon 1A and intron 1. 
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